A team from Khalifa University has created a novel electrochemical immunosensor that simultaneously detects monkeypox. Its selectivity, low detection limits, and field-ready design make it a promising tool for decentralized monkeypox diagnosis
Mpox (monkeypox) is a viral infection closely related to smallpox that has seen multiple international outbreaks since 2022. Current gold-standard diagnostic tools like PCR are accurate but require centralized lab infrastructure, while rapid tests often lack the precision necessary to confidently identify cases, especially during the early stages of infection.听
In response to the urgent need for better mpox diagnostics, researchers at Khalifa University have developed a novel electrochemical biosensor capable of detecting two key antigens simultaneously. The sensor achieves high sensitivity and specificity, outperforming many existing diagnostic technologies. Most importantly, it can be used out in the field.听
Pandiaraj Kanagavalli, Ragi Adham Elkaffas and Dr. Shimaa Eissa published their results in . Their system measures changes in electrochemical current caused by antigen binding, enabling accurate readings within just 30 minutes.听
“We can detect monkeypox in a fast, reliable, and low-cost way by targeting two viral proteins. Our biosensor will be especially useful in settings where traditional lab tests are not accessible.”
鈥� Shimaa Eissa, Assistant Professor, Khalifa University
听
Mpox early symptoms resemble those of other respiratory viruses, including fever, fatigue, and headache, which can complicate early diagnosis. The KU team鈥檚 new biosensor addresses these limitations. By immobilizing antibodies for the M1R and A29 proteins 鈥� two key mpox antigens 鈥� onto an engineered reduced graphene oxide/metal organic framework nanocomposite surface, the researchers created a diagnostic platform that is both portable and robust. It demonstrates strong selectivity with no cross-reactivity to proteins from other viruses like influenza or SARS Cov-2. Plus, its low cost means it could be deployed in point-of-care settings, particularly in regions with limited access to laboratory resources.听
This study is the first to develop a biosensor capable of detecting the M1R protein and the first to combine M1R and A29 detection on a single platform. By targeting two antigens, the device reduces the likelihood of false negatives, a critical advantage for outbreak control and early diagnosis.
Jade Sterling
Science Writer
